Long-Term Risk of Skin Cancer and Lymphoma in Users of Topical Tacrolimus and Pimecrolimus: Final Results from the Extension of the Cohort Study Protopic Joint European Longitudinal Lymphoma and Skin Cancer Evaluation (JOELLE)

References

• Örtqvist A, Lundholm C, Wettermark B, Ludvigsson J, Ye W, Almqvist C. Validation of asthma and eczema in population-based Swedish drug and patient registers. Pharmacoepidemiol Drug Saf. 2013;22(8):850–860. doi:10.1002/pds.346523754713
   PubMed Web of Science ®Google Scholar
• Asgari MM, Tsai AL, Avalos L, Sokil M, Quesenberry CP Jr. Association between topical calcineurin inhibitor use and keratinocyte carcinoma risk among adults with atopic dermatitis. JAMA Dermatol. 2020;156(10):1066–1073. doi:10.1001/jamadermatol.2020.224032785626
   PubMed Web of Science ®Google Scholar
• Castellsague J, Kuiper JG, Pottegard A, et al. A cohort study on the risk of lymphoma and skin cancer in users of topical tacrolimus, pimecrolimus, and corticosteroids (Joint European Longitudinal Lymphoma and Skin Cancer Evaluation - JOELLE study). Clin Epidemiol. 2018;10:299–310. doi:10.2147/CLEP.S14644229559812
   PubMed Web of Science ®Google Scholar
• Lam M, Zhu JW, Tadrous M, Drucker AM. Association between topical calcineurin inhibitor use and risk of cancer, including lymphoma, keratinocyte carcinoma, and melanoma: a systematic review and meta-analysis. JAMA Dermatol. 2021;157(5):549–558. doi:10.1001/jamadermatol.2021.034533787818
   PubMed Web of Science ®Google Scholar
• Tennis P, Gelfand JM, Rothman KJ. Evaluation of cancer risk related to atopic dermatitis and use of topical calcineurin inhibitors. Br J Dermatol. 2011;165(3):465–473. doi:10.1111/j.1365-2133.2011.10363.x21466537
   PubMed Web of Science ®Google Scholar
• Arana A, Wentworth CE, Fernandez-Vidaurre C, Schlienger RG, Conde E, Arellano FM. Incidence of cancer in the general population and in patients with or without atopic dermatitis in the U.K. Br J Dermatol. 2010;163(5):1036–1043. doi:10.1111/j.1365-2133.2010.09887.x20545690
   PubMed Web of Science ®Google Scholar
• Arellano FM, Wentworth CE, Arana A, Fernandez C, Paul CF. Risk of lymphoma following exposure to calcineurin inhibitors and topical steroids in patients with atopic dermatitis. J Invest Dermatol. 2007;127(4):808–816. doi:10.1038/sj.jid.570062217096020
   PubMed Web of Science ®Google Scholar
• Brookhart Ma, Schneeweiss S, Rothman KJ, Glynn RJ, Avorn J, Sturmer T. Variable selection for propensity score models. Am J Epidemiol. 2006;163(12):1149–1156. doi:10.1093/aje/kwj14916624967
   PubMed Web of Science ®Google Scholar
• Sturmer T, Wyss R, Glynn RJ, Brookhart MA. Propensity scores for confounder adjustment when assessing the effects of medical interventions using nonexperimental study designs. J Intern Med. 2014;275(6):570–580. doi:10.1111/joim.1219724520806
   PubMed Web of Science ®Google Scholar
• Rothman KJ, Greenland S, Lash TL, eds. Modern Epidemiology. 3rd ed. Philadelphia: Lippincott Williams & Wilkins; 2008.
   Google Scholar
• Gutierrez L, Booth H, Dedman D, et al. Case validation of cutaneous lymphoma to minimize protopathic bias. Poster presented at the 35th Annual ICPE Conference; August 27, 2019; Philadelphia, Pennsylvania.
   Google Scholar
• Berg D, Otley CC. Skin cancer in organ transplant recipients: epidemiology, pathogenesis, and management. J Am Acad Dermatol. 2002;47(1):1–17;quiz 18-20. doi:10.1067/mjd.2002.12557912077575
   PubMed Web of Science ®Google Scholar
• Hartevelt MM, Bavinck JN, Kootte AM, Vermeer BJ, Vandenbroucke JP. Incidence of skin cancer after renal transplantation in The Netherlands. Transplantation. 1990;49(3):506–509. doi:10.1097/00007890-199003000-000062316011
   PubMed Web of Science ®Google Scholar
• Jensen P, Hansen S, Moller B, et al. Skin cancer in kidney and heart transplant recipients and different long-term immunosuppressive therapy regimens. J Am Acad Dermatol. 1999;40(2 Pt 1):177–186. doi:10.1016/S0190-9622(99)70185-410025742
   PubMed Web of Science ®Google Scholar
• Mittal A, Colegio OR. Skin cancers in organ transplant recipients. Am J Transplant. 2017;17(10):2509–2530. doi:10.1111/ajt.1438228556451
   PubMed Web of Science ®Google Scholar
• Zwald FO, Brown M. Skin cancer in solid organ transplant recipients: advances in therapy and management: part I. Epidemiology of skin cancer in solid organ transplant recipients. J Am Acad Dermatol. 2011;65(2):253–261; quiz 262. doi:10.1016/j.jaad.2010.11.06221763561
   PubMed Web of Science ®Google Scholar
• Hui RL, Lide W, Chan J, Schottinger J, Yoshinaga M, Millares M. Association between exposure to topical tacrolimus or pimecrolimus and cancers. Ann Pharmacother. 2009;43(12):1956–1963. doi:10.1345/aph.1M27819903860
   PubMed Web of Science ®Google Scholar
• Schneeweiss S, Doherty M, Zhu S, et al. Topical treatments with pimecrolimus, tacrolimus and medium- to high-potency corticosteroids, and risk of lymphoma. Dermatology. 2009;219(1):7–21. doi:10.1159/00020928919293564
   PubMed Web of Science ®Google Scholar
• Margolis DJ, Abuabara K, Hoffstad OJ, Wan J, Raimondo D, Bilker WB. Association between malignancy and topical use of pimecrolimus. JAMA Dermatol. 2015;151(6):594–599. doi:10.1001/jamadermatol.2014.430525692459
   PubMed Web of Science ®Google Scholar
• Manthripragada A. Addendum: update on calcineurin inhibitor pediatric literature review (FDA briefing document). Office of Surveillance and Epidemiology, FDA Center for Drug Evaluation and Research, Food and Drug Administration; May 10, 2011. Available from: https://wayback.archive-it.org/7993/20170114054651/http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/PediatricAdvisoryCommittee/UCM255140.pdf. Accessed September 19, 2019.
   Google Scholar
• Paller AS, Folster-Holst R, Chen SC, et al. No evidence of increased cancer incidence in children using topical tacrolimus for atopic dermatitis. J Am Acad Dermatol. 2020;83(2):375–381. doi:10.1016/j.jaad.2020.03.07532246968
   PubMed Web of Science ®Google Scholar
• von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandenbroucke JP. STROBE Initiative. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. J Clin Epidemiol. 2008;61(4):344–349.18313558
   PubMed Web of Science ®Google Scholar